Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Medical supervision ensures appropriate dosing protocols, monitoring for cognitive improvements, assessment of safety parameters, and integration with comprehensive brain health strategies including proper nutrition, sleep optimization, cognitive training, and lifestyle modifications that support long-term neurological wellness and cognitive performance enhancement
A post-workout meal or shake containing 30 to 50 grams of protein supports training adaptations
Different patient populations, different enrollment criteria, different sites, and different measurement protocols all introduce variability that makes direct numerical comparison imprecise
US$ 21.31
US$ 25.23
US$ 23.96
